Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma

Jacqueline Vuky, Richard Yu, Lawrence Schwartz, Robert J. Motzer

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with arsenic trioxide (As2O3). Eligible patients had metastatic renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70%, life expectancy of greater than three months, and no evidence of brain metastases. Arsenic trioxide was given intravenously at a dose of 0.3 mg/kg/day for five consecutive days every four weeks. The most common toxicity observed was grade II elevation in liver function tests (36%), anemia (21%), renal insufficiency (14%), rash (7%), and diarrhea (7%). Best response was stable disease in 3 patients with one patient remaining on study at 8+ months At the dose and schedule used in this trial, arsenic trioxide did not achieve a complete or partial response in metastatic renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)327-330
Number of pages4
JournalInvestigational New Drugs
Issue number3
StatePublished - 2002
Externally publishedYes


  • Arsenic trioxide
  • Metastatic renal cell carcinoma
  • Phase II trial

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this